Note on additional diagnostic characters for Marphysa sanguinea (Montagu, 1813) (Annelida: Eunicida: Eunicidae), a recently introduced species in the Netherlands

Recently specimens of the polychaete Marphysa sanguinea (Montagu, 1813) (Annelida: Eunicida: Eunicidae) were reported as an introduction to the Eastern Scheldt in southwestern Netherlands. In order to confirm the species identity, material was examined with SEM and compared with material from Devon near the type locality in Cornwall, UK. These studies confirmed that this was a new record of M. sanguinea, which can be distinguished from other Marphysa species by the pattern of the distribution of pectinate chaetae in posterior parapodia. This new record extends the known distribution of the species based on verified records, eastward along the English Channel. As the specimens from the Netherlands show additional variation, the species description of M. sanguinea is expanded, which will facilitate future identifications of this species and comparison with other members of the genus.

Yousefi, S., Rahimian, H., Nabavi, S.M.B. & Glasby, C.J. (2011) Nereididae (Annelida: Polychaeta from intertidal habitats in the Gulf of Oman, Iran. Zootaxa, 3013, 48-64.

Yousefi, S., Rahimian, H., Nabavi, S.M.B., Glasby, C.J. (2013): Yousefi, S., Rahimian, H., Nabavi, S.M.B. & Glasby, C.J. (2011) Nereididae (Annelida: Polychaeta from intertidal habitats in the Gulf of Oman, Iran. Zootaxa, 3013, 48-64. Zootaxa 3636 (3): 500-500, DOI: 10.11646/zootaxa.3636.3.8, URL: http://dx.doi.org/10.11646/zootaxa.3636.3.

The effect of a liberal approach to glucose control in critically ill patients with type 2 diabetes: a multicenter, parallel-group, open-label randomized clinical trial

Rationale: Blood glucose concentrations affect outcomes in critically ill patients, but the optimal target blood glucose range in those with type 2 diabetes is unknown. Objectives: To evaluate the effects of a “liberal” approach to targeted blood glucose range during ICU admission. Methods: This mutlicenter, parallel-group, open-label randomized clinical trial included 419 adult patients with type 2 diabetes expected to be in the ICU on at least three consecutive days. In the intervention group intravenous insulin was commenced at a blood glucose >252 mg/dl and titrated to a target range of 180–252 mg/dl. In the comparator group insulin was commenced at a blood glucose >180 mg/dl and titrated to a target range of 108–180 mg/dl. The primary outcome was incident hypoglycemia (<72 mg/dl). Secondary outcomes included glucose metrics and clinical outcomes. Measurements and Main Results: By Day 28, at least one episode of hypoglycemia occurred in 10 of 210 (5%) patients assigned the intervention and 38 of 209 (18%) patients assigned the comparator (incident rate ratio, 0.21 [95% confidence interval (CI), 0.09 to 0.49]; P < 0.001). Those assigned the intervention had greater blood glucose concentrations (daily mean, minimum, maximum), less glucose variability, and less relative hypoglycemia (P < 0.001 for all comparisons). By Day 90, 62 of 210 (29.5%) in the intervention and 52 of 209 (24.9%) in the comparator group had died (absolute difference, 4.6 percentage points [95% CI, −3.9% to 13.2%]; P = 0.29). Conclusions: A liberal approach to blood glucose targets reduced incident hypoglycemia but did not improve patient-centered outcomes. Clinical trial registered with Australian New Zealand Clinical Trials Registry (ACTRN 12616001135404)